| 标题 |
 Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊：The Lancet Respiratory Medicine 作者：Ross Andrew Soo; Sanjay Popat; Urania G. Dafni; Adrianus Johannes De Langen; Ernest Nadal; et al 出版日期：2026-10-01 |
| 求助人 | |
| 下载 | 求助已完成，仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)
皖公网安备34019202002308
